Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New head of Swiss devices agency:

This article was originally published in Clinica

Executive Summary

Margit Widmann is to take over as the head of the medical devices division at the Swiss competent authority, Swissmedic, later this year. A biochemist by training, Mrs Widmann has many years of industry experience in the medical devices sector. She will take over the role from Isabel Scuntaro, who has been acting head since Rainer Voelksen was seconded to the Australian medtech agency, the TGA, in mid-2005, and who has now joined Synthes (see Clinica No 1223, p 10). Dr Scuntaro did not seek to take over the position on a permanent basis for personal reasons, she explained to Clinica, and is looking forward to returning to her prime responsibilities in clinical trial management within Swissmedic. She will continue to work closely with chief inspector for medical devices Markus Zobrist.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT052917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel